Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new treatment options.
This type of breast cancer tests positive for higher levels of a protein called HER2.'use strict';CNN.Videx=CNN.Videx || {};CNN.Videx.mobile={};CNN.INJECTOR.executeFeature.then {CNN.VideoPlayer.handleUnmutePlayer=function handleUnmutePlayer {'use strict';var playerInstance,playerPropertyObj,rememberTime,unmuteCTA,unmuteIdSelector='unmute_' + containerId,isPlayerMute;dataObj=dataObj || {};if ==='fave') {playerInstance=FAVE.player.
Cancer: The facts 01:00One study, published in the New England Journal of Medicine last week, found that adding the experimental drug tucatinib to a chemotherapy regimen consisting of the drugs trastuzumab and capecitabine could improve survival for adults with advanced HER2-positive metastatic breast cancer.
Cancer & Complementary Therapies 03:21Read More"What's so exciting is we have developed multiple new drugs for HER2-positive breast cancer -- we have new drugs for all subtypes of breast cancer -- but the changes are most dramatic in the setting of HER2-positive breast cancer," Winer said. "It is the single area in breast cancer where we have made the most dramatic progress and continue to," he said.
Dr. Ian Krop, a principal investigator of the study and associate chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston, called the research results"striking" in a press release on Wednesday."These results are particularly striking as trastuzumab deruxtecan prompted a high level of durable tumor reduction among patients, the majority of whom had exhausted most if not all standard therapies for HER2-metastatic breast cancer," he said.
good like